



Our STN: BL 125127/992

SUPPLEMENT APPROVAL

GlaxoSmithKline Biologicals
Attention: Leslie Sands
14200 Shady Grove Road
VR 1500
Rockville, MD 20850-7464

March 20, 2020

Dear Ms. Sands:

We have approved your request submitted and received September 19, 2019, to supplement your Biologics License Application (BLA) under section 351(a) of the Public Health Service Act for Influenza Vaccine (Fluarix), manufactured at your Dresden, Germany facility to include the proposed language related to the concomitant administration of Fluarix Quadrivalent with Zoster Vaccine Recombinant, Adjuvanted (Shingrix) vaccine in your package insert.

We hereby approve the draft package insert labeling submitted under amendment 3, dated March 19, 2020.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

All final labeling should be submitted as Product Correspondence to this BLA STN 125127 at the time of use (prior to marketing) and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that includes this change.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

Doran L. Fink
Deputy Director-Clinical
Division of Vaccines and
Related Products Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research